References
- Yataco JC, Dweik RA. Pleural effusions: evaluation and management. Cleve Clin J Med. 2005;72(10):854–6.
- Light RW. Pleural diseases. 6th ed. Lippincott Williams & Wilkins; 2013.
- National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–85.
- Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20(4):250–78.
- Mizutani H. MRSA-related empyema as thoracic surgical site infection. Kansenshogaku Zasshi. 2009;83(5):506–12.
- Molnar TF. Current surgical treatment of thoracic empyema in adults. Eur J Cardiothorac Surg. 2007;32(3):422–30.
- Choo EJ, Chambers HF. Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Infect Chemother. 2016;48(4):267–73.
- Suzuki H, Shomura S, Sawada Y, Shimamoto A, Kondo C, Takao M, Shimpo H. Therapeutic strategy for acute pleural empyema: comparison between retrospective study and prospective study. Gen Thorac Cardiovasc Surg. 2019;67(12):1048–55.
- Ramirez P, Fernández-Barat L, Torres A. New therapy options for MRSA with respiratory infection/pneumonia. Curr Opin Infect Dis. 2012;25(2):159–65.
- Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 2004;30(3):388–94.
- Estes KS, Derendorf H. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010;15(12):533–43.
- Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621–9.
- Rebai L, Fitouhi N, Daghmouri MA, Bahri K. Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant Staphylococcus. Surg Neurol Int. 2019;10:215.
- Cosgrove SE, Vigliani GA, Campion M, Fowler, Jr VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48(6):713–21.
- Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, Ishihara M, Ikeuchi H, Uchino M. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–7.
- Chen C, Guo D-H, Cao X, Cai Y, Xu Y, Zhu M, Ma L. Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73(6):195–206.
- Niki Y. Japanese Association for infectious disease. Practical guidelines for the management and treatment of infections caused by MRSA, the 2nd Edition. Kansenshogaku Zasshi. 2014;88(5):597–68. ;
- Pertel PE, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M, Thorne GM, Luperchio SA, Arbeit RD, Alder J, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis. 2008;46(8):1142–51.